Clinical trials: PAH
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension
This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality)…
- Trial name
- NCT07232368
- Testing
- Slow-paced breathing intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Ege University
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with…
- Trial name
- EPITOME-1 (NCT01105091)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Volunteers
- 30 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension (PAH)
Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertension
This is an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled clinical trial.
- Trial name
- ALEPH (NCT06987097)
- Testing
- Ambrisentan
- Volunteers
- 410 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension (PAH), Comorbidities
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
- Trial name
- COMMODITIES (NCT07245680)
- Testing
- Tadalafil, Ambrisentan
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension, Right Heart Failure
Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension.
- Trial name
- REHAB-PH (NCT03554291)
- Testing
- Famotidine 20 MG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Washington
Systemic Sclerosis, Pulmonary; Hypertension
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
A double-blinded, placebo-controlled study of Dimethyl fumarate (DMF) in 34 Systemic Sclerosis-Pulmonary Hypertension (SSc-PAH) patients.
- Trial name
- NCT02981082
- Testing
- Dimethyl Fumarate (DMF)
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Robert Lafyatis
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Hypertension, Pulmonary, Hypertension;Pulmonary;Primary
Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
Measurement of the endtidal carbon dioxide by capnography to exclude or to ensure the diagnosis pulmonary hypertension. The aim of the study is to obtain an endtidal carbon dioxide cut-off value for the diagnostic algorithm for…
- Conditions
- Hypertension, Pulmonary, Hypertension;Pulmonary;Primary, Chronic Thromboembolic Pulmonary Hypertension, Vascular Diseases
- Trial name
- EARLIER (NCT03388476)
- Testing
- Capnography
- Where
- Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Giessen
Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension
Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension
Background and Rationale: Sleep-disordered breathing and nocturnal hypoxemia are highly prevalent in patients with precapillary pulmonary hypertension (PH), and current guidelines recommend systematic sleep assessment in this…
- Conditions
- Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Sleep-disordered Breathing, Nocturnal Hypoxemia
- Trial name
- HRV&PH (NCT07464184)
- Testing
- Standard Clinical and Functional Assessment, Overnight Polysomnography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Rouen
Phenylketonuria, Mild Hyperphenylalaninemia
Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study
Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood.
- Trial name
- NCT01924026
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- The Hospital for Sick Children
Hypertension, Pulmonary
Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH
The aim of research proposal is to assess and compare the safety and efficacy of radiofrequency denervation of pulmonary arteries on decrease in pulmonary vascular resistance and mean pulmonary artery pressure (MPAP) in 20…
- Trial name
- CADOPA (NCT02403908)
- Testing
- nMARQ Circular and Crescent catheters
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- Clinical Hospital Centre Zagreb
Pulmonary Arterial Hypertension
Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is characterized by a progressive increase in pulmonary vascular resistance inducing shortness of breath and exercise intolerance.
- Trial name
- FONCE-HTAP (NCT02579954)
- Testing
- Rehabilitation
- Where
- 10 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
The purpose of this study is: To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT04994119
- Testing
- BIA 5-1058, Warfarin
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil…
- Trial name
- TRITON (NCT02558231)
- Testing
- Macitentan, Tadalafil, Selexipag
- Where
- 58 sites in United States, Australia and 13 more
- Volunteers
- 247 people
- Sponsor
- Actelion
Pulmonary Hypertension
Mexican Registry of Pulmonary Hypertension
Prospective multicenter registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and four years follow-up outcome through major adverse…
- Trial name
- REMEHIP (NCT02252705)
- Volunteers
- 875 people
- Sponsor
- Remehip
Takayasu Arteritis, Pulmonary Artery Hypertension
Pulmonary Artery Involvement in Takayasu's Arteritis
The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of…
- Trial name
- NCT03189602
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Lung Diseases, Hypertension, Pulmonary
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension
The goal of this study is to identify the modifying genes and environmental features that regulate the clinical expression of mutations in bone morphogenetic protein receptor 2 (BMPR2); to develop the understanding of how BMPR2…
- Trial name
- NCT00091546
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- Vanderbilt University
Pulmonary Artery Hypertension
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
Pulmonary hypertension Group 2 (PH 2) associated with left-sided heart disease is relatively common, is associated with a poor prognosis, and unfortunately there are no proven medical treatments beyond attempts at correcting the…
- Trial name
- NCT02684786
- Testing
- reserpine, stellate ganglion block, lidocaine
- Where
- United States
- Sponsor
- Mayo Clinic
Idiopathic Pulmonary Hypertension
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
This study aims to compare the effectiveness and safety of two treatment approaches for patients with severe pulmonary hypertension: standard targeted drug therapy alone, and a combination of standard targeted drugs plus Qishen…
- Trial name
- NCT07604805
- Testing
- Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangdong Provincial People's Hospital